Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events

Covid19 Clinical Trial

— iGenes-COVID19  

Official title:

Investigating the Involvement of ACE and Angiotensinogen Genes' Polymorphism Along With Other Thrombophilic Genotypes in Severe Forms of COVID-19 With/Without Thrombotic Events

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04519398
• Other study ID #: GTP0051
• Status: Recruiting
• Start date: August 18, 2020
• Est. completion date: August 18, 2021

Study information

• Verified date: August 2020
• Source: Grigore T. Popa University of Medicine and Pharmacy
• Contact: Alexandru Burlacu, MD, PhD
• Phone: 00407444488580
• Email: alexandru.burlacu[@]umfiasi.ro
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

An estimated 22% of the global population is at an increased risk of a severe form of COVID-19, while one in four coronavirus patients admitted to intensive care unit will develop a pulmonary embolism. A major public health question remains to be investigated: why COVID-19 is mild for some, critically severe for others and why only a percentage of COVID-19 patients develop thrombosis, despite the disease's proven hypercoagulable state? Patients' intrinsic characteristics might be responsible for the deep variety of disease forms.

Our study aims to assess the validity of the hypothesis according to which underlining genetic variations might be responsible for different degrees of severity and thrombotic events risks in the novel coronavirus disease.

Moreover, we suspect that prothrombotic genotypes occuring in the genes that encode angiotensin-converting enzyme (ACE-DEL/INS) and angiotensinogen (AGT M235T) are involved in the unpredictable evolution of COVID-19, both in terms of severity and thrombotic events, due to the strong interactions of SARS-CoV-2 with the renin-angiotensin-aldosterone system (RAAS). Therefore, we also aim to assess the validity of the theory according to which there is a pre-existing atypical modulation of RAAS in COVID-19 patients that develop severe forms and/or thrombosis.

Our hypothesis is based on various observations. Firstly, there is a substantial similarity with a reasonably related condition such as sepsis, for which there is a validated theory stating that thrombophilic mutations affect patients' clinical response. Secondly, racial and ethnic genetic differences are responsible for significant dissimilar thrombotic risks among various nations. Thirdly, an increase in stroke incidence has been reported in young patients with COVID-19, without essential thrombosis risk factors, favoring the idea that a genetic predisposition could contribute to increase the thrombotic and thromboembolic risk. Fourthly, the plasminogen activator inhibitor (PAI)-1 4G/5G inherited mutation was found to be responsible for a thrombotic state causing post-SARS osteonecrosis.

Description:

The study's protocol will cover the following steps:

• Collected data from COVID-19 patients at admission will include:

• Descriptive general demographic data

• Previous pathologies and thrombosis risk factors

• Routine biological data (the blood routinely collected will also be used for SARS-Cov-2 specific RT-PCR exam)

Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes:

• Factor V Leiden

• Factor V 4070 A G (Hr2)

• Factor II G20210A

• Methylenetetrahydrofolate reductase (MTHFR) C677T

• MTHFR A1298C

• Cystathionine β-synthase (CBS) 844ins68

• PAI-1 4G/5G

• Glycoprotein IIIa T1565C (HPA-1a/b)

• ACE-DEL/INS

• Apolipoprotein E (ApoE)

• AGT M235T

• Angiotensin II type 1 receptor (ATR-1) A1166C

• Fibrinogen - 455 G A

• Factor XIII Val34Leu SpO2, respiratory rate, PaO2/FiO2 RAAS components

• Imagistic procedures (chest X-ray or CT)

• All patients with a positive SARS-CoV-2 PCR test will be included

• Patients will be divided into three groups depending on disease severity and the presence of thrombotic state:

• 1st group includes COVID-19 patients with proved

• venous thrombosis (deep vein thrombosis, pulmonary embolism or venous thrombosis occurring in more atypical places such as in the veins of the brain, liver, kidney, mesenteric vein and the veins of the arms)

• or arterial thrombosis (heart attacks, strokes)

• 2nd group encompasses asymptomatic patients and those with mild or moderate disease, according to current guidelines, without thrombosis: no symptoms or evidence of lower respiratory disease by clinical assessment or imaging and a SpO2 ≥ 94%

• 3rd group includes severe disease, according to current guidelines, without thrombosis: respiratory frequency > 30 breaths per minute, SpO2 < 94%, PaO2/FiO2 < 300 mmHg, or lung infiltrates >50%

• Statistical methods will be employed to check for significant differences between prothrombotic mutations frequency and RAAS components levels for the three groups

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: August 18, 2021
• Est. primary completion date: February 17, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All hospitalized patients with cough, fever, myalgia - with confirmed COVID-19 infection • All patients with a positive SARS-CoV-2 PCR test

Exclusion Criteria:

• Patient refusal

• Uncertain tests results

• Children

Related Conditions & MeSH terms

• ARDS
• Corona Virus Infection
• Coronavirus Infections
• Covid19
• Intracranial Thrombosis
• RAAS
• Severe Acute Respiratory Syndrome
• Thrombophilia
• Thromboses, Deep Vein
• Thromboses, Intracranial
• Thrombosis
• Venous Thrombosis

Intervention

Genetic:
• Complete thrombophilic profile testing by multiplex PCR
Complete thrombophilic profile testing by multiplex PCR and reverse hybridization of DNA to assess the presence of prothrombotic genotypes: Factor V Leiden Factor V 4070 A>G (Hr2) Factor II G20210A Methylenetetrahydrofolate reductase (MTHFR) C677T MTHFR A1298C Cystathionine ß-synthase (CBS) 844ins68 PAI-1 4G/5G Glycoprotein IIIa T1565C (HPA-1a/b) ACE-DEL/INS Apolipoprotein E (ApoE) AGT M235T Angiotensin II type 1 receptor (ATR-1) A1166C Fibrinogen - 455 G>A Factor XIII Val34Leu

Locations

Country	Name	City	State
Romania	University of Medicine and Pharmacy Gr T. Popa Iasi, Romania	Iasi

Sponsors (1)

Lead Sponsor	Collaborator
Grigore T. Popa University of Medicine and Pharmacy

Country where clinical trial is conducted

Romania, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with thrombophilic profile alterations	The difference of prothrombotic genotypes frequency between the three groups	One year
Secondary	Number of patients with RAAS components alterations	The differences of RAAS components levels between the three groups	One year